Recombinant Teduglutide(Chongqing Paijin Bio)

重组替度鲁肽（重庆派金生物科技）

Report date: 2024/07/23 17:55:28
First In Class

Base Information

Drug NameRecombinant Teduglutide(Chongqing Paijin Bio)
Drug Alias Nameteduglutida替度鲁肽teduglutidum特度鲁肽PJ009 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 2 receptor agonists
TargetsGlucagon-like peptide 2 receptor
Therapy Area/IndicationsShort Bowel Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChongqing Peg-Bio Biopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Peg-Bio Biopharm Co Ltd
Inactive CompaniesN/A
Active IndicationsShort Bowel Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG